Optimización de la elección de talla para el segundo ojo basándose en el vault obtenido en el primero en la cirugía bilateral de lentes fáquicas de cámara posterior / Optimization of the lens sizing for the second eye based on the vault obtained in the first eye in bilateral myopic collamer phakic intraocular lens surgery

OBJETIVO: Evaluar el vault y la toma de decisiones en la selección del tamaño de la lente del segundo ojo en una serie de pacientes que recibieron implantes bilaterales de una lente fáquica de cámara posterior (pIOL) con puerto central para la corrección de la miopía. MÉTODOS: La muestra del estudio incluyó los pacientes a los que se implantó una pIOL de diferente tamaño entre ambos ojos de una serie total de 269 pacientes intervenidos mediante inserción bilateral secuencial en nuestra institución entre marzo de 2012 y mayo de 2015. Los procedimientos en cada paciente fueron separados en el tiempo para seleccionar el tamaño de la pIOL en los segundos ojos. El vault fue analizado objetivamente mediante tomografía de coherencia óptica. RESULTADOS: La decisión de modificar el tamaño de la pIOL se tomó en 25 pacientes. En 9 pacientes se implantó una pIOL más pequeña en el segundo ojo, mientras que en 16 pacientes se necesitó una talla más grande. La implantación de una talla más grande condujo a un aumento medio del vault de 251 ± 180 micras, mientras que una lente de menor tamaño se tradujo en una disminución media del vault de 542 ± 187 micras. En 5 pacientes, la pIOL implantada en el primer ojo se rotó verticalmente para reducir el vault. No fue necesario explantar ninguna lente. CONCLUSIONES: El vault en los ojos adelfos de pacientes intervenidos bilateralmente con una pIOL miópica puede ser optimizado valorando la talla a implantar en el segundo ojo en función del vault obtenido en el primer ojo

PURPOSE: To assess vault and the decision-making process involved in selecting the size of the lens for the fellow eye in a series of patients who received bilateral phakic collamer intraocular lens (pIOL) implants with central hole for correction of myopia. METHODS: The study sample included all patients who underwent bilateral insertion of a different size pIOL from a pool of 269 patients who underwent sequential bilateral insertion of a pIOL from March 2012 to May 2015 in our institution. Procedures were separated in time to assess the value of the vault and select the pIOL size in second eyes. Vault was analysed objectively using optical coherence tomography. RESULTS: The decision to change the size of the pIOL in the fellow eye was taken in 25 patients. A smaller pIOL was implanted in the second eye in 9 patients, whereas a lens that was 1 size larger was necessary in 16 patients. Implantation of a larger lens led to a mean increase in vault of 251 ± 180 microns; implantation of a smaller size lens led to a mean decrease in vault of 542 ± 187 microns. In 5 patients, the pIOL implanted in first eye was rotated vertically to reduce lens vault. No lenses had to be explanted. CONCLUSIONS: Vault in fellow eyes can be improved in patients receiving bilateral myopic pIOL implants by modifying the pIOL size based on the vault value obtained in the first eyes

Optimization of the lens sizing for the second eye based on the vault obtained in the first eye in bilateral myopic collamer phakic intraocular lens surgery. / Optimización de la elección de talla para el segundo ojo basándose en el vault obtenido en el primero en la cirugía bilateral de lentes fáquicas de cámara posterior.

PURPOSE: To assess vault and the decision-making process involved in selecting the size of the lens for the fellow eye in a series of patients who received bilateral phakic collamer intraocular lens (pIOL) implants with central hole for correction of myopia. METHODS: The study sample included all patients who underwent bilateral insertion of a different size pIOL from a pool of 269 patients who underwent sequential bilateral insertion of a pIOL from March 2012 to May 2015 in our institution. Procedures were separated in time to assess the value of the vault and select the pIOL size in second eyes. Vault was analysed objectively using optical coherence tomography. RESULTS: The decision to change the size of the pIOL in the fellow eye was taken in 25 patients. A smaller pIOL was implanted in the second eye in 9 patients, whereas a lens that was 1 size larger was necessary in 16 patients. Implantation of a larger lens led to a mean increase in vault of 251 ± 180 microns; implantation of a smaller size lens led to a mean decrease in vault of 542 ± 187 microns. In 5 patients, the pIOL implanted in first eye was rotated vertically to reduce lens vault. No lenses had to be explanted. CONCLUSIONS: Vault in fellow eyes can be improved in patients receiving bilateral myopic pIOL implants by modifying the pIOL size based on the vault value obtained in the first eyes.

[Comparative study of the prevalence of hepatitis B virus infection and human immunodeficiency virus type 1 infection in the prison population between 1985 and 1992]. / Estudio comparativo de la prevalencia de infección por virus de la hepatitis B y virus de la inmunodeficiencia humana tipo 1 en la población penitenciaria entre 1985 y 1992.

The prisoner population of the penitentiaries presents an elevated prevalence of hepatitis B virus (HBV) and human immunodeficiency type 1 (HIV-1) infection markers. In the last few years different measures have been developed to prevent infection. This study evaluates whether there have been changes in the prevalence of infection by these virus over the last few years within a penitentiary. A group of prisoners (n = 163) studied in 1985 were therefore compared with another group (n = 750) studied in 1992. Demographic, social, risk and penitentiary factors were included. In each of the subjects studied alanine aminotransferase (ALT), hepatitis B virus (HBsAG, antiHBs and antiHBc) and anti-HIV-1 markers were determined. It was globally observed that following the 7 years between the two studies there was a decrease in the prevalence of HBV (X = 14.63, p = 0.0001, OR = 2; CI 95%: 1.38-2.9), which was mainly observed in the group of prisoners with no drug addiction habits. No differences were observed with regard to the prevalence of anti-HIV-1 which remained similar among the IV drug consumers and not consumers (64% and 66.6% in 1985 and 1992, respectively). In conclusion, from 1985 to 1992 a decrease has been observed in the prevalence of hepatitis B virus infection in the penitentiary population while the prevalence of anti-HIV-1 has remained unchanged.

[The hepatitis C virus among the prison population of Valencia]. / Virus C de la hepatitis entre la población penitenciaria de Valencia.

AIM: To know the prevalence of anti-VHC in the Valencia Male Penitentiary Centre. DESIGN: A prospective study in which a representative sample of the inmates is included. In each case the anti-VHC and the ALT are studied. Serological results were correlated with history of intravenous drug addiction, alcohol abuse and duration and number of internments. INMATES: 750 inmates are included; they represent 41% of the people interned in this Centre during 1991. RESULTS: A high prevalence (45%) of the serological marker for VHC infection was observed. The prevalence of anti-VHC+ among the drug addict inmates is around 90% and this situation was already found during the first year of drug addiction. Among non-drug addict inmates the prevalence is 14%. Hepatitis C virus infection has a correlation with the duration and number of internments; 75% of the inmates with high ALT values have anti-VHC+. CONCLUSIONS: Nearly half of the inmates are infected with hepatitis C virus. The drug addict inmates are infected during the first year of their habit. The majority of the inmates with elevated ALT has anti-VHC+.

Prevalence of liver disease and infection by hepatitis B, delta virus, and human immunodeficiency virus in two Spanish penitentiaries.

We studied the prevalence of liver disease and the carrier state for hepatitis B (HBV), delta virus (HDV) and HIV-1 infection in two Valencian penitentiaries, one for males and the other for females. Serological results were correlated with history of intravenous drug addiction, alcohol abuse, homosexuality or prostitution (high-risk groups), and duration and number of internments. A high prevalence of increased transaminase levels (52.2%) and serological markers for HBV infection (66.5%) was observed amongst the inmates, figures being higher amongst high-risk individuals and inmates confined for more than 6 months. No signs of HDV or HIV-1 infection were found amongst the prison staff. Anti-HIV-1 positivity was observed most frequently amongst individuals combining both drug abuse and homosexuality/and prostitution.